Literature DB >> 1708513

Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia.

R Brancato1, A Pece, P Avanza, E Radrizzani.   

Abstract

The authors performed a prospective study of 36 eyes affected by pathologic myopia with macular subretinal neovascularization (SRNV) successfully treated with either argon green, dye orange (590 nm), or krypton red lasers. Re-treated eyes were excluded. Evolution of the laser scar was carefully monitored for 12 months. Scar expansion was noted in 35 cases (97%), without a significant loss of visual acuity during the first year after treatment. The scar enlarged more conspicuously during the first 3 months after photocoagulation, with a mean increase of 103% in the first year. Expansion was not related to laser wavelength, patient age, SRNV size, or degree of myopia. Scar enlargement was greatest in the same direction as that of maximal extension of the myopic peripapillary crescent; inspection of the morphologic configuration of the peripapillary crescent before laser treatment may be helpful in evaluating the potential risk of post-laser scar expansion toward the fovea.

Entities:  

Mesh:

Year:  1990        PMID: 1708513     DOI: 10.1097/00006982-199010000-00002

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.

Authors:  J M Ruiz-Moreno; C de la Vega
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

2.  Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization.

Authors:  Joseph R Ferencz; Gila Gilady; Orly Harel; Michael Belkin; Ehud I Assia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-23       Impact factor: 3.117

Review 3.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

4.  Current status in diabetic macular edema treatments.

Authors:  Pedro Romero-Aroca
Journal:  World J Diabetes       Date:  2013-10-15

Review 5.  Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Authors:  Ying Zhu; Ting Zhang; Gezhi Xu; Lijun Peng
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

6.  Indirect scatter laser photocoagulation to subfoveal choroidal neovascularization in age-related macular degeneration.

Authors:  J Arnold; M Algan; G Soubrane; G Coscas; E Barreau
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-04       Impact factor: 3.117

7.  Safety and efficacy of selective retina therapy (SRT) for the treatment of diabetic macular edema in Korean patients.

Authors:  Young Gun Park; Jae Ryun Kim; Seungbum Kang; Eric Seifert; Dirk Theisen-Kunde; Ralf Brinkmann; Young-Jung Roh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-23       Impact factor: 3.117

8.  Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes.

Authors:  J M Ruiz-Moreno; J A Montero
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

9.  Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia.

Authors:  Francesco Bandello; Paolo Lanzetta; Maurizio Battaglia Parodi; Derri Roman-Pognuz; Sandro Saviano; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-18       Impact factor: 3.117

10.  The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation.

Authors:  Somaia Mitne; Sergio Henrique Teixeira; Michal Schwartz; Michael Belkin; Michel Eid Farah; Nilva S Bueno de Moraes; Luciana da Cruz Nóia; Angela Tavares Paes; Cláudio Luiz Lottenberg; Augusto Paranhos Júnior
Journal:  Clin Ophthalmol       Date:  2011-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.